
Keywords: alloSCT; allogeneic stem cell transplant; AML; acute myeloid leukemia; ESA; erythropoiesis-stimulating agent; FDA; Food and Drug Administration; FISH; fluorescence in situ hybridization; G-CSF; granulocyte colony stimulating factor; HSCT; hematopoietic st